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Abstract
We present a powerful experimental-computational technology for inferring network models that predict the response of
cells to perturbations, and that may be useful in the design of combinatorial therapy against cancer. The experiments are
systematic series of perturbations of cancer cell lines by targeted drugs, singly or in combination. The response to
perturbation is quantified in terms of relative changes in the measured levels of proteins, phospho-proteins and cellular
phenotypes such as viability. Computational network models are derived de novo, i.e., without prior knowledge of
signaling pathways, and are based on simple non-linear differential equations. The prohibitively large solution space of all
possible network models is explored efficiently using a probabilistic algorithm, Belief Propagation (BP), which is three
orders of magnitude faster than standard Monte Carlo methods. Explicit executable models are derived for a set of
perturbation experiments in SKMEL-133 melanoma cell lines, which are resistant to the therapeutically important inhibitor
of RAF kinase. The resulting network models reproduce and extend known pathway biology. They empower potential
discoveries of new molecular interactions and predict efficacious novel drug perturbations, such as the inhibition of PLK1,
which is verified experimentally. This technology is suitable for application to larger systems in diverse areas of molecular
biology.
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Introduction
Signaling in cancer cells
Abnormal biomolecular information flow as a result of genetic
or epigenetic alterations may lead to tumorigenic transformation
and malignancy and is classically modeled as changes in
signaling pathways [1]. Targeted anti-cancer drugs, which bind
and inhibit specific components of aberrant signaling pathways,
are a promising alternative to conventional chemotherapy, with
recent successes in melanoma (RAF inhibitor) [2] and prostate
cancer (AR inhibitor) [3,4] following in the footsteps of the
pioneering BCR-ABL inhibitor Imatinib [5] and EGFR inhib-
itors Gefitinib and Erlotinib [6,7,8]. Combinations of targeted
anticancer drugs hold considerable promise because of the
emergence of resistance to initially successful single agents and
the highly robust nature of the signaling pathways with multiple
feedback mechanisms [9].
Data-driven models of cell biology
High throughput measurements on response profiles of living
cells to multiple perturbations such as drug combinations provide
a rich set of information to construct quantitative cell biology
models. In this paper, we construct context specific de novo
mathematical models of signaling pathways through the use of
systematic paired perturbation experiments and network inference
algorithms. Such network models provide insight into mechanistic
details of signaling pathways, predict the response of cellular
systems to multiple perturbations beyond those from which models
are derived, and guide the design of perturbations for a desired
response.
State of the art in network inference in cell biology
Previous mathematical models of molecular signaling in cells
have been effective in modeling pathways and enhancing drug
discovery [10,11,12,13,14,15,16,17,18,19]. Techniques for net-
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work modeling of signaling pathways span a wide spectrum of
complexity. Detailed chemical kinetics and spatiotemporal
models [17,20,21] can provide mechanistic explanations of
observed behavior, but are often incompletely parameterized,
needing tens or hundreds of sensitive parameters for medium-
sized systems. Moreover, such models may not be valid in
biological contexts that differ substantially from dilute solution
chemistry. On the other end of the spectrum, pattern matching or
machine learning models such as neural networks and correla-
tion-based models such as maximum entropy [22] can accurately
provide purely data-driven models of signaling. However, such
methods have limited power to explain mechanistic details and,
in most cases, are insufficient for quantitative predictions of
system behavior in conditions beyond those from which the
models are derived.
Data-driven and context-specific predictive models
We take a unique modeling approach to construct context
specific, de novo and predictive network models of signaling
pathways from drug perturbation data (Figure 1). Here, de novo
means that network inference is done without depending on
known molecular interactions extracted from literature or pathway
databases, which do not account for biological context. This
approach also emphasizes context specificity since it relies on rich
experimental data from a single biological context as its training
set. The models are constructed through parameterization of a
simple model equation, which has been used in other network
modeling approaches [13,23,24,25,26,27]. The model equations
contain parameters that are mechanistically descriptive of direct or
indirect interactions in the system. Finally, the models are
computationally predictive of cell-type specific response to new
drug perturbations and their combinations. We expect that this
conceptual framework and the technical advances in network
inference will empower the community to identify unique drug
targets and combinations that are particularly efficacious within
specific disease contexts.
Network modeling de novo or with prior information
De novo construction of signaling network models at scales
relevant to problems related to complex biological phenomena
such as cancer has long been a challenge in system biology. Thus,
quantitative models of protein signaling pathways are typically
constructed on the basis of existing prior knowledge from literature
searches [16,17] and interaction databases [19,28,29]. However,
different cancer contexts have unique genetic and proteomic
Author Summary
Drugs that target specific effects of signaling proteins are
promising agents for treating cancer. One of the many
obstacles facing optimal drug design is inadequate
quantitative understanding of the coordinated interactions
between signaling proteins. De novo model inference of
network or pathway models refers to the algorithmic
construction of mathematical predictive models from
experimental data without dependence on prior knowl-
edge. De novo inference is difficult because of the
prohibitively large number of possible sets of interactions
that may or may not be consistent with observations. Our
new method overcomes this difficulty by adapting a
method from statistical physics, called Belief Propagation,
which first calculates probabilistically the most likely
interactions in the vast space of all possible solutions,
then derives a set of individual, highly probable solutions
in the form of executable models. In this paper, we test
this method on artificial data and then apply it to model
signaling pathways in a BRAF-mutant melanoma cancer
cell line based on a large set of rich output measurements
from a systematic set of perturbation experiments using
drug combinations. Our results are in agreement with
established biological knowledge, predict novel interac-
tions, and predict efficacious drug targets that are specific
to the experimental cell line and potentially to related
tumors. The method has the potential, with sufficient
systematic perturbation data, to model, de novo and
quantitatively, the effects of hundreds of proteins on
cellular responses, on a scale that is currently unreachable
in diverse areas of cell biology. In a disease context, the
method is applicable to the computational design of novel
combination drug treatments.
Figure 1. Perturbation cell biology. Perturbing cancer cells with targeted drugs singly and in pairs (A) reveals context-specific response to
therapies and illuminates protein interactions. We construct dynamic mathematical models of the cells’ response to drugs that have both
quantitative parameters (B) and a qualitative network interpretation (C). We use an inference algorithm called Belief Propagation (BP) to construct a
set of good, i.e., predictive models (D).
doi:10.1371/journal.pcbi.1003290.g001
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alterations to normal protein signaling. For example, distinct
mutations in effector proteins of the PI3K pathway are oncogenic
in unique ways, i.e., they lead to distinctly context dependent
functional consequences in different cancer types, subtypes and
patients [30]. The method we introduce here is capable of
inferring parameterized network models with prior knowledge, yet
the results in this study do not include prior knowledge. An
advantage of de novo inference is independence from prior
knowledge interactions that may be incorrect or incomplete in a
particular biological context.
Model inference from perturbation data for larger
systems is hard
The largest obstacle to de novo model construction is the
combinatorial explosion in the number of possible network
models, which defines the solution space [31]. Model inference
problems of this type are NP-hard [32]. The number of possible
configurations for a model with N nodes, and K possible values for
each parameter grows super-exponentially as KN
2
. We have
previously described a method named CoPIA for de novo
construction of dynamic nonlinear network models from pertur-
bation data [33]. CoPIA is based on the combined use of a Monte
Carlo stochastic search algorithm, which is used to search the
network configurations and an efficient gradient descent algorithm
[34] for quantitative parameter optimization. However, without
algorithmic improvements, such Monte Carlo based methods are
limited to modeling fewer than approximately 15–20 biological
entities [33]. Increasing the scale of network (or pathway) models
of cellular signaling processes to levels sufficient to describe
complex biological problems in quantitative detail is therefore
extremely challenging and has been approached with a diversity of
methods [35].
A statistical physics approach can handle the complexity
for larger systems
An ingenious, two-step approach to deal with network
inference in larger systems is based on first calculating probability
distributions for each possible interaction in the model and then
computing distinct solutions by sampling these probability
distributions. For this purpose, we employ a probability model
of network configurations inspired from statistical physics
principles. Following a set of approximations to simplify the
probability model, we apply a custom adaptation of an iterative
algorithm called Belief Propagation (BP). BP involves local
optimization updates to probability distributions of individual
model parameters that converge to a stable set of probability
distributions, which collectively describe a set of good network
model solutions [36,37,38]. BP has been applied to various
complex inference problems, some of them NP-Hard such as K-
SAT [38] and graph coloring [39]. BP has garnered some
attention in biological network inference [40,41] and parameter
estimation [42,43]. Here, we tailor the BP algorithm to large-
scale perturbation data that is capable of increasing the scope of
the models to hundreds of nodes. The result of BP is a set of
probability distributions for each model parameter, often referred
to as marginal probability distributions, or ‘marginals’. Each
marginal describes the inferred distribution of a particular
parameter across a range of high probability solutions. Individual
models are created via sampling from these marginals [44].
Consequently, the time-complexity of the problem is strongly
reduced, the prohibitive cost from combinatorial complexity is
circumvented and, although the method provides only an
approximate solution, one obtains useful, non-trivial results.
In practice: from systematic perturbation to response
profiling to network model inference
Our algorithmic network pharmacology approach involves four
major steps: (i) perturbation experiments with combinations of
targeted compounds; (ii) high-throughput quantitative measure-
ments of proteomic changes (e.g., reverse phase protein arrays or
mass spectrometry) and phenotypic changes (e.g., cell viability or
apoptosis); (iii) inference of quantitative network models of protein
signaling that explain and link these changes; and (iv) use of the
network models to predict cellular and molecular responses to
diverse perturbations, beyond the conditions on which the network
models are derived.
Experimental and computational technology for network
model inference and application to drug effects on
melanoma cell lines
In this work, we adapt BP to construct quantitative network
models of signaling pathways from systematic perturbation
experiments. We evaluate the speed and accuracy of BP on toy
data generated from biologically inspired network structures. The
inference on this toy data reveals that BP offers a significant
improvement in computational efficiency compared to traditional
Monte Carlo simulations without a sacrifice in accuracy.
Furthermore, we construct network models of signaling in a
RAF inhibitor resistant melanoma cell line (SKMEL-133), which
has the BRAFV600E mutation [45,46]. The models are predictive
of both the proteomic and phenotypic response to drug
combinations. Model simulations successfully predict the pheno-
typic response profiles of SKMEL-133 cells to novel drug targets.
With the introduction of many novel targeted drugs and patient
specific genomic profiling, this network pharmacology approach
aims to provide an effective tool to develop individualized
combination therapies against multiple cancer forms.
Results
Theory
Mathematical framework of the network model. Key
decisions in modeling a biological cellular system include the
choice of variables and the mathematical framework for repre-
senting system dynamics. Here, we work with a fairly simple but
powerful ansatz or framework, in which the time behavior of the
cellular system {xi(t)} in a set of perturbation conditions {ui
m} is
modeled as a series of coupled non-linear differential equations
(Equation 1) [33].
Equation 1: Non-linear network model for the time behavior of the cellular
system
dx
m
i tð Þ
dt
~eiw
XN
j=i
wijx
m
j tð Þzumi
 !
{aix
m
i tð Þ
w(z)~tanh(z)
ð1Þ
The system variables x represent quantities of particular
biological entities one wishes to measure and model. In this work,
quantities are restricted to relative changes in protein and
phospho-protein abundances and cell viability levels. The
variables are nodes in the network model. The model parameters
w in the matrix W formally quantify the interactions between
nodes and correspond to directed edges in the network model.
Equation 1 includes an independent time variable t, which denotes
that variables are functions of time. The term u represents an
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external force on a model variable, which models interventions
from targeted drug perturbations. A vector of u-values defines the
set of targeted perturbations; combinations are simple additions of
these vectors. In principle, u is time-dependent, but not in the
current implementation. The variable index i maps to a single
network node, and the experimental index (m) maps to a single
experimental perturbation condition. A biological system is
therefore modeled by a collection of coupled equations of the
form defined in Equation 1. Perturbations to any node propagate
in time through the network interactions producing trajectories
x(t), which present the behavior of the system over time.
Theoretically, the model variables can quantify any measure of
interest. While absolute protein concentrations are one option,
such data is difficult to acquire in high throughput assays. In this
study, we focus on log2-ratios of abundances in perturbed
conditions to abundances in the unperturbed condition. Conse-
quently, model variables can take both negative and positive
values, which denote decreased or increased quantities of the
corresponding biological entity. We choose to normalize all
measurement levels against unperturbed levels in order to focus
on signaling differences due directly to perturbation.
The rate of change of any variable, in this formulation, is
predominantly influenced by the additive linear combination of
upstream nodes {xj} weighted by their respective interaction
strength {wij}. Only non-zero values of wij are interactions in the
network model. We incorporate nonlinearity with a sigmoidal
function w(z) that limits both the maximum positive and negative
rates of change [24], controlled by the parameter e. The a
parameter models the rate of restoration at which a model variable
would return to its initial value before perturbation, in the absence
of interactions. This is analogous to the degradation rate in models
of positively valued protein concentrations. The parameters e and
a are not inferred with BP. For the remainder of this section they
are assumed to be 1, and are dropped from the equations. They
are reintroduced in the final stage of modeling, when individual
models are optimized with gradient descent.
The network models are parameterized by the square interac-
tion matrix W={wij} of size N (N
2 entries), where wij represents a
directed interaction between nodes, quantifying the influence of xj
on the rate of change of xi. In chemical kinetics, the wij is analogous
to rate constants in units of inverse time, although no explicit rates
are derived here. Equation 1 describes the dynamic behavior of
the system, given a constant interaction matrixW. In this work, we
explicitly forbid self-interactions, therefore the N diagonal entries
of W are set to 0 and only the remaining N2-N are subject to
fitting. These apparently simple models can represent biologically
realistic regulatory motifs, such as serial and parallel pathway
connectivity, positive and negative feedback loops and feed-
forward control. The models used here are dynamic in the sense
that they can be simulated as temporal trajectories that converge
to a steady state. In this work, the parameters are inferred based
solely on data assumed to represent the biological steady state.
Thus, only the endpoints of the simulated trajectories are
constrained. Despite not being used in this study, both the model
and the learning method can generalize to incorporate time-series
data.
The problem of model inference. The problem of deriving
useful models of a (biological) system is called ‘model inference’.
The objective of model inference, given a mathematical frame-
work like that described above, is to find a set of parameters such
that the model equations best reproduce a training set of
experimental data and have predictive power beyond the training
set. In the present modeling framework, we aim to find numerical
values for the N2–N free parameters in the interaction matrix W,
such that descriptive and predictive power of the model is
optimized. Genuine predictive power, rather than just descriptive
power, requires both low error and low complexity of the model,
combined as low cost. We quantify the cost of W by an objective
cost function C(W) that penalizes: (i) discrepancies between
predicted x
m
i (tl) and experimentally measured x
m
i (tl) values of
the system observables at a set of time points {tl} in condition m;
and (ii) the number of non-zero interactions in W. Lower cost
models tend to have more predictive power than higher cost
models.
Equation 2: Model configuration cost function
C(W)~b
XL
l
XN
i
XM
m
x
m
i (tl){x
m
i (tl)
 2
zl
XN
i
XN
j=i
d(wij) ð2:aÞ
d(wij)~1 if wij=0
d(wij)~0 if wij~0
ð2:bÞ
C(W) is thus the error-plus-complexity cost of a parameter
configuration W. The cost components are weighted by b and l,
respectively. The complexity cost term is an L0 penalty
[47,48,49,50,51] that penalizes non-zero entries in W and is
included to both avoid overfitting and reflect the empirical
observation that realistic biological networks such as gene
regulatory networks or protein-protein interaction networks are
sparse [52]. While L1 penalties are convex and therefore amenable
to efficient convex optimization methods, they are not used here
since they provide weaker constraint on the complexity of the
interaction matrix W [25,53,54,55]. We do not wish to include
direct self-interaction in the present version; thus, the sum in the
complexity term does not include the diagonal elements wii. The
computational challenge of network inference is to translate the
information contained in a set of experimental observations into
an optimal set of models, as represented by a set of low cost
interaction matrices W. In this report, we work in the steady-state
approximation and thus ignore the time variable in the cost
function in Equation 2.
De novo network inference is a hard problem. In
principle, to infer optimal network configurations one has to
compute the cost of all possible network configurations. However,
explicit enumeration and cost calculation of all possible parameter
configurations W is a prohibitively complicated task for even
moderately sized systems. To estimate the complexity of this task,
assume that any wij can take on K discrete values out of a value
range V, for example, V={21,0,+1} for K=3, representing
inhibition, no interaction and activation, respectively. As the
number of model nodes N increases, the number of possible
parameter configurations increases as KO(N
2). Even for moderate
N, e.g., 20 nodes, the number of distinct configurations is of order
10190, obviously a very large number, making explicit enumeration
prohibitive.
The solution space refers to the set of all possible model
configurations. A reasonably clever strategy to traverse this
enormous solution space is guided random exploration, e.g., by
a traditional Monte Carlo search, in which random moves in
multi-dimensional parameter space are kept or rejected based on
the cost of the resulting configuration, with a non-zero but small
probability of accepting higher cost configurations in order to
facilitate the escape from local minima. In an earlier study, we
successfully used a Monte Carlo search followed by a modified
Perturbation Cell Biology
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gradient descent method to derive a set of low cost models for a
relatively small system. This earlier algorithm achieved a
reasonable exploration of solution space for a system of 14
variables, as assessed by the recurrence of dominant interactions
across the set of a few hundred low-cost models and the agreement
of those interactions with well-established knowledge of signaling
pathways in cell biology. However, the KO(N
2)argument above and
explicit computational benchmarking indicate that such Monte
Carlo searches become prohibitively expensive for larger systems.
Fast inference via a probability model of network
configurations. In search of a more efficient algorithm, we
adopt an idea originally developed in statistical physics, and widely
used in solving complicated optimization problems in computer
science and other areas. Instead of sampling a prohibitively large,
unrestricted solution space by traversing a set of individual
configurations, the idea is to first calculate high probability regions
and then restrict exploration to this smaller solution space. In
particular, we describe high probability regions by calculating
probability distributions of individual model parameters over
possible value assignments. Then, we can generate distinct model
configurations by sampling from the calculated probability
distributions.
Models with a large error (or cost) have low probability, while
those with a low error have high probability. More precisely, the
probability of any particular model can be computed from its cost,
which depends on the parameters in the interaction matrixW and
the experimental data (Equation 2). In statistical physics, there is
an analogous relationship between the Hamiltonian for the states
of a system and its Boltzmann-Gibbs probability distribution over
all states. In terms of Bayesian inference, the equation below
relates the posterior distribution of the model on the left to the
likelihood function and prior distributions on the right.
Equation 3: The probability model of network configurations
P(W)~
1
Z
e{C Wð Þ~
1
Z
e
{b
PN
i
PM
m
(x
m
i
{x
m
i
)2
e
{l
PN
i~1
PN
j=i
d(wij )
The variable Z is the partition function, which ensures that the
sum of the probabilities over all model configurations is equal to
one. In the statistical physics analogy, the exponents contain
interaction energies and the parameter b is an inverse temperature
(1/T), such that higher values of b assign higher probability to
lower cost configurations. The parameter l is the weight of the
complexity penalty. The choice of b and l is non-trivial and is an
open area of research (see Methods). Given the probabilistic model
in Equation 3, the practical challenge is to identify configurations
of model parameters in W that represent maximally probable
models, given the data. The explicit computation of probabilities
for all possible sets of parameters is not feasible even for
moderately sized (N.15) systems. One therefore has to invent
practical algorithms for effectively exploring the total solution
space and approximately determining sets of good models.
Iterative optimization of the probability model. An
effective solution is to use an iterative algorithm to approximate
the probability distributions of the individual parameters by
themselves, often called marginal probability distributions, or
simply ‘marginals’. From these marginals, we can describe high
probability model configurations for the full system. This iterative
algorithm begins with a set of random marginals. In each iteration
step, one assumes approximate knowledge of all parameter
marginals (‘global information’) and then performs optimization
updates on an individual marginal (‘local update’). The local
update takes immediate effect and becomes part of the ‘global
information’ for successive iterations as the algorithm traverses
over all marginals for individual updating. The iteration termi-
nates when it converges to a stable set of marginals. The nature of
any local update to a single parameter (e.g., a node-node
interaction parameter) is a calculation optimizing a balance of
fitness to experimental data and consistency with the global
information. The iterative application of this ‘global to local and
back’ optimization strategy results in marginals for all system
parameters given a probabilistic model. Such optimal marginals
are informative by themselves, but are also useful for constructing
a population of explicit individual high probability model
configurations, which are useful for model simulation studies.
This type of probabilistic method originates in statistical physics
and has been generalized to a number of hard optimization
problems in statistical physics and computer science. An early
application of such probabilistic inference was inverse parameter
inference for disordered diluted spin systems [56,57,58]. A well
known formulation in terms of Bayesian statistics led to the term
‘belief propagation’ [59] (BP).
The BP approach, also known as the Bethe-Peierls approxima-
tion or cavity method in statistical physics, provides an approximate
method for computing marginal probability distributions on a class
of probabilistic graphical models called factor graphs. In general, a
joint probability distribution over many variables may factorize into
a product of factors. A factor in a factor graph represents an
independent contribution to the joint probability distribution, and is
connected to the variables that depend on that factor. Typically, a
factor defines a constraint on a subset of variables. The BP method
is proven to be exact on tree-shaped factor graphs. It has many
useful applications in approximating distributions on sparse factor-
graphs [60,61] where the influence of loops in the factor graph is
expected to be weak. More recently, several applications to dense,
loopy factor-graphs have been proposed [40,62,63,64,65]. The
problem we address here is a dense factor graph, where each factor
is connected to N variables, which in this framework are the model
parameters in Equation 1 (Figure 2).
A major advantage of BP algorithms is the reduction of
computational complexity. This not only leads to a substantial
reduction in computational effort for smaller systems but also
opens the door to solving inference problems for larger systems,
which would otherwise be prohibitive.
Simplified probability model of network configu-
rations. We use a series of assumptions, described below, to
factorize the probability model in Equation 3 into a form that can be
efficiently calculated without sacrificing the quantitative and predic-
tive nature of the models. The assumptions below reduce the problem
from a probability distribution over whole model configurations
(Equation 3) into a collection of marginal probability distributions for
each individual parameter. Subsequent sampling from these individ-
ual marginals will result in efficient exploration of high probability
model configurations.
Assumption 1: Discrete set of real valued parameter
assignments. To simplify the probability model, we compute
the probability distributions for model parameters over discrete
values, from a set V, rather than for continuous values. The choice
of discretization is an important detail and affects the convergence
properties of the BP algorithm and the quality of the resulting
marginals. Empirically, with the data set at hand we find that a set
of 11 discrete values, centered at zero, rarely fails to converge to a
stable set of marginals. Conversely, searching over only 3 weight
values results in a high rate of non-convergence. As for the quality
of the resulting marginals, the entropies are close to zero if we limit
the search to only 3 discrete values (see Supplemental Text S1).
Perturbation Cell Biology
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The entropy is a statistical measure of the uncertainty in
distributions, such that zero entropy distributions imply absolute
certainty, i.e., each parameter is predicted to be 100% zero or
100% non-zero. This is an undesirable quality; one wants the BP
marginals to constrain a set of highly probable solutions, not
return one model configuration. In practice, discretizing with 11
weights gives intuitively reasonable marginals and balances the
restriction and exploration of solution space. In the final stage of
network inference strategy, we refine the set of discrete valued
model parameters to solutions with continuous model parameters
using a local gradient descent optimization algorithm [33].
Assumption 2: Decoupling of variables at steady
state. In the dynamic model, the system variables are coupled
such that a change to any variable propagates to all others via the
time derivatives as in Equation 1. A rigorous way to compute the
fitness of a configuration is to simulate a configuration and then
compare simulation output to the training data. Such a
computation, while feasible in principle, is very costly. An
alternative is to take advantage of the relationship at the steady
state (Equation 4) where the time-derivative is equal to zero.
Equation 4: Model equation at steady state
x
m
i~w
XN
j=i
wijx
m
jzu
m
i
 !
for all variables i and experiments m
Equation 4 is a system of self-consistent equations for all variables
{xi}. To avoid having to do numerical simulation, we replace {xj
m}
on the right hand side of Equation 4 with experimentally observed
{xj
m*} at the expense of self-consistency (Equation 5).
Equation 5: Approximate model equation at steady-state
x
m
i~w
XN
j=i
wijx
m
j zu
m
i
 !
Figure 2. Iteration process for Belief Propagation. Top panel: the global information consists of collecting the probability distributions of the
non-cavity parameters without the contribution from the cavity condition. This is a simple product over all rn(wij) factors except that from the cavity
constraint m. Distributions centered on zero denote unlikely interactions (see j = 2), centered on the right of zero denote likely positive interactions
(see j = 3), and centered on the left denote likely negative interactions (see j = N). These distributions inform the parameters of the Gaussian
distribution for the mean-field, aggregate sum variable smk . The distribution P
m(s
m
k) summarizes the state of the non-cavity parameters. Bottom panel:
we calculate the probability of each possible parameter assignment v[V to the cavity parameter wik constrained to the data in the cavity condition.
This calculation boils down to a simple convolution of the fitness function with a fixed parameter assignment Fm(smk) with the probability of the
aggregate sum variable Pm(smk), obtained by integrating over all values of s
m
k . Each assignment v[V contributes proportional to the area under the
curve. The resulting update is the contribution of condition m on the distribution of wik , denoted r
m(wik). This recently updated distribution becomes
part of the global information for successive updates to other parameters.
doi:10.1371/journal.pcbi.1003290.g002
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This approximation decouples the variables from each other:
the model predicted value of x
m
i depends only on the parameters in
the ith row of the interaction weight matrixW and on the set {xj
m*}
of experimentally measured values in condition m. Thus, the
posterior probability P(W) can be factorized as a product of
independent posterior probability distributions over configurations
of individual rows of the weight matrix. Consequently, we have an
independent probability distribution for each row of the interac-
tion weight matrix Wi~ wi1, . . . ,wiNf g. These rows describe
interactions from variables xj Vj[f1 . . .Ng to the single variable
xi. The resulting factorized expressions are:
Equation 6a–d: Probability model of configurations with decoupled nodes
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We introduce the notation Fm(Wi) to denote the fitness of the
model configuration Wi to the data from experimental m. It is
important to note that the posterior probability distribution in
Equation 6d factorizes over the fitness functions, such that Fm(Wi)
contributes independently to the full probability distribution of
that configuration. The probability distribution in 6d, however,
does not factorize any further, since each parameter wik in Wi
depends on the other parameters in Wi. In order to reach good
solutions for 6d without enumerating all configurations Wi, we
apply an iterative method to infer marginals for the constituent
parameters {wij V j}.
Belief Propagation algorithm: Iterative updates of
probability estimates. As already mentioned above, the BP
method consists of randomly ordered updates to the marginal
probabilities for individual parameters, one at time. Updates
continue until convergence, when the marginal probabilities do
not change between consecutive updates. We describe the method
in detail below for single Wi since the procedure is independent
and identical for all rows i[f1 . . .Ng due to Assumption 2. The
update calculation is schematically diagramed in Figure 2.
Local updates with global information. A local update
takes place inside an abstract ‘cavity’, which isolates a single
parameter whose marginal distribution is to be updated (wik) and
data from a single experimental condition (m). The global
information is simply the most up-to-date approximation of the
marginal distributions for all the other parameters plus the
experimental data. A local update optimizes the balance between
fitting the experimental data in the cavity condition m and
compatibility with global information, which evolves as the
algorithm iterates. A single distribution is locally updated in one
step and becomes part of the global information for updating
other distributions in successive steps. This local update is
repeated in all possible cavities (i.e. all combinations of
parameters and conditions) until global convergence of the
distributions is reached.
Recall that we are optimizing parameters in a single row of W
so for the following equations the index i is fixed. We define rm(wij)
to be a factor, which is a probability distribution of a single
parameter that describes its fitness to the data in a single
experiment m that is compatible with the other parameters. By
definition, each factor is independent so that the final marginal is
simply the product of all of its factors.
The BP algorithm begins with random rm(wij) for all m and j.
The initial choice of cavity parameter (wik) and cavity condition (m)
is also random. Once the cavity is selected, the algorithm collects
the global information, which is simply the set of approximations
for the marginal probabilities of all the other model parameters
(Equation 7). They are approximate in two ways: they lack the
contribution from the cavity factor m; and until the algorithm
converges, the factors collectively do not describe the true
marginal distribution.
Equation 7: Global information of non-cavity parameters
Pm(wij)~
1
Zij
e{ld(wij )PMn=mr
u(wij) Vj=k
d(wij)~0 if wij~0
d(wij)~1 if wij=0
The exponent ld(wij) is an independent penalty for non-zero
parameter assignments, which encodes prior knowledge that any
parameter is likely to be zero. The superscript m in Pm(wij) denotes
the exclusion of the contribution from experimental condition m.
In the following step, the factor rm(wik) is updated to fit the data in
a single experiment m given the global information.
Calculating local update to rm(wik). We define Wi\k to be a
configuration of the ith row of W where the parameter wik is fixed
to some value v. The factor rm(wik) reflects the fitness of the
parameter with Wi\k weighted by the probability of observing the
particular configuration (Wi\k) as in Equation 8.
Equation 8: Local update to probability distribution of
cavity parameter
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In the field of optimization algorithms, these equations are
sometimes referred to as messages because they communicate
information between variable nodes and factor nodes on the factor
graph, where in this case the variable nodes in the factor graph
correspond to model parameters. Thus, BP belongs to a class of
‘message-passing’ algorithms. It is common to see Equation 7
referred to as messages from the variable nodes to the factor nodes
and denoted Pj?m(wij). Similarly, Equation 8 can be thought of as
a message update from a factor node to a variable node, denoted
rm?k(wik).
Assumption 3: Independent model parameter
distributions. Equation 8 is the mathematical definition of
the factor distribution rm(wik). However, a brute force approach for
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calculating rm(wik) as in Equation 8a is computationally prohib-
itive. The first complication is that computation of the joint-
probability distribution Pm(Wi\k) is not possible if we consider the
interdependencies of the non-cavity parameters. To circumvent
this problem, we assume that in the context of the local update,
each parameter probability distribution is independent. Then the
joint probability distribution can be approximated as the product
of the individual parameter distributions.
Equation 9: Approximation of the joint distribution for the cavity update
Pm(Wi\k)~ P
N
j=k
Pm(wij)
Therefore, Equation 8 becomes Equation 10.
Equation 10: Local update with factorized probability distributions
rm(wik~v)~
X
Wi\k
Fm(Wi\k) P
N
j=k
Pm(wij)
 
This equation is equivalent to the sum-product formulation,
which is standard in BP literature [60]. It is important to note that
the assumption that the joint probability distribution factorizes as
the product of individual distributions (Equation 9) is exact on
tree-shaped factor graphs, but is only an approximation in general.
This assumption does not extend beyond the context of the cavity
update calculation.
Assumption 4: Gaussian mean-field approxima-
tion. Another complication in Equation 10 is that a brute force
implementation of the sum operation requires enumeration over
an exponentially large number of configurations, which in total is
KN-1. Here, we replace the sum over multivariate configurations
(Wi\k) with an integral over a single scalar variable (s
m
k). To achieve
this, we substitute the fitness function’s dependence on the
multivariate configuration Wi\k with a single scalar variable s
m
k.
This substitution is explicitly defined in Equation 11, where the
new variable s
m
k represents the aggregate contribution of the non-
cavity parameters to the fitness.
Equation 11: Aggregate effect of non-cavity parameters
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To complete the substitution ofWi\k for s
m
k in Equation 10, we also
require a description of the probability distribution for the new
variable i.e., P(s
m
k). Note that the dependence of s
m
k on Wi\k is
through a linear combination of the individual parameters (Equation
11.b), which by assumption 3 are independently distributed. We
invoke the central limit theorem to approximate P(s
m
k) as a Gaussian
[66]. The mean and variance of this Gaussian are described by the
means and variances of the distributions Pm(wij) Vj=k. Thus, we
replace the sum over multivariate configurations (Equation 10) with
the Gaussian integration of s
m
k (Equation 12).
Equation 12: Gaussian integration of local update to cavity parameter
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The explicit calculation of Pm(s
m
k) is described in Equations 13a–
d, where the over-bar denotes the arithmetic mean.
Equations 13a–d: Statistical description of mean-field parameters
Pm(s
m
k)~
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2pDmk
q e{
s
m
k
{s
m
k
 2
2D
m
k ð13:aÞ
s
m
k~
XN
j=i,k
wijx
m
j zu
m
i ð13:bÞ
Dmk~
XN
j=i,k
wij
2{w2ij
 
(x
m
j )
2 ð13:cÞ
wij~
X
v
vPm(wij~v) ð13:dÞ
Iteration of update equations. In summary, the following
BP equations are calculated for each cavity update iteratively until
convergence.
Equations 14a–b: Update equations
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Calculation of parameter probability distributions. When
the above iterative process converges, the final marginals are
calculated from the set of factors, reflecting the information from
experimental constraints.
Equation 15: Final marginal calculation
P(wij)~e
{ld(wij )P
M
m
rm(wij)
The BP algorithm provides marginals characterizing a set of
good models. Thus, we reduce the unbounded model search space
to a set of tractable probability distributions for model parameters.
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Next, one must generate high probability models by drawing from
the BP calculated marginals.
Network model instantiation by BP guided
decimation. We need distinct model solutions to proceed with
predictive and quantitative analysis of signaling pathways via
explicit model simulations. Distinct solutions are derived by the BP
guided decimation algorithm [44]. The decimation algorithm
works as follows: (i) an initial BP is run to compute probability
distributions P(wij) for all possible interactions; (ii) a possible
interaction (suppose an edge that connects node k and node l) and
an associated edge value (wkl =v) is chosen with probability
proportional to the corresponding BP marginal; (iii) a subsequent
round of BP is run with P(wkl=v) = 1; (iv) steps i–iii are repeated
until an edge value is fixed for all possible interactions in the
system. Parallel repetition of this procedure generates any number
of network models with varying configurations and error profiles.
The non-zero parameters in each model are further optimized
using a gradient descent algorithm, which relaxes the discretiza-
tion of parameter values and further lowers the error by fine-
tuning the real number values of the parameters. Moreover, the
gradient descent refinement ensures that the network models are
mathematically in steady state and the nodes in the network
models are fully coupled [33]. Each model is then a set of
differential equations describing the behavior of the system in
response to perturbations.
Direct vs. Indirect Interactions. Due to limitations in
experimental measurements, not all proteins and their many
phosphorylated states are directly measureable. The result is that
many key intermediate players are excluded from the model. For
this reason, direct interactions in our model do not necessarily
imply direct biological interactions (Supplemental Figure S15).
Increasing the number and quality of protein and phospho-protein
measurements increases the chance of modeling direct interac-
tions.
Technical performance
The success of BP depends on whether or not the simulations of
the models taken from BP are quantitatively predictive of cellular
response to drug combinations. It is also useful, as an exercise, to
evaluate the overall performance of the BP algorithm on data sets
engineered from completely known networks. With such toy
datasets we achieve the following: (i) demonstrate that BP
converges quickly and correctly; (ii) compare BP network models
to a known data-generating network; and (iii) evaluate perfor-
mance in biologically realistic conditions of noisy data from sparse
perturbations. The synthetic data is generated without the
assumptions used in the formulation of BP, and therefore serves
as a reasonable test of the sensitivity of the BP method to those
assumptions. See methods for more information on how the toy
data is generated.
Belief Propagation is fast and accurate. Monte Carlo
(MC) simulation and optimization is a strategy for sampling the
space of explicit solutions, in which full parameter configurations
are searched as a whole. Short of infinite coverage, a thorough
MC search yields reasonably accurate approximations of the ‘true’
probability distributions: both posterior probability distributions of
explicit configurations, and marginal probabilities of individual
parameters, which are calculated by counting the frequency of any
parameter assignment across the set of good solutions. MC is a
frequently used optimization strategy in statistical physics, and
thus a valuable candidate for comparison. We examine speed and
accuracy performance of MC and BP for increasingly large
models. To do this, one toy data generator is constructed for each
of the ten different sizes from N=10 to N=100. In each case, the
number of training patterns equals the number of nodes for
consistency of comparison, i.e., M=N. Both methods search a
very large parameter space of 41 possible parameter assignments
with V~f{2,{1:9, . . . ,1:9,2:0g; thus for this toy dataset the
search space of all configurations is of size 41N.
The first criterion of interest is time of convergence (Figure 3A).
For both methods, the time required for convergence increases as
the size of the system increases, but MC is consistently three orders
of magnitude slower than BP. The speed advantage of BP is vital
for our ability to scale up the size of de novo model construction for
biological systems with hundreds of nodes.
The second criterion is accuracy. While we are interested
primarily in the accuracy of predicting responses to new
perturbations, we are also interested in the accuracy of the
inferred interactions as an indicator of the models’ explanatory
and predictive power. In practice, we find that BP does no worse
than MC on these datasets given reasonable termination
conditions for MC (Supplemental Text-S2).
A Pearson correlation coefficient between the set of non-zero
parameters in the data generators and the average values inferred
by BP is a reasonable measure of agreement between true and
inferred parameters. BP results in a correlation of R= 0.7,
(Figure 3B) which is quite high considering the relatively small
Figure 3. BP is significantly faster than Monte Carlo (MC) with
comparable accuracy. (A) BP converges three orders of magnitude
faster than MC, even as the size of the system increases to 100 nodes. In
this test, the number of training patterns equals the number of nodes in
both BP and MC. (B) The means of the distributions from BP are plotted
against the true non-zero parameters from the set of the data
generators. BP has a high correlation (R = 0.7) with the true parameter
values, with many points exactly on the diagonal. (C) MC and BP
produce low errors per data point compared to random interaction
assignments (Red bar).
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number of training patterns used for each inference (M=N). As
the number and quality of training pattern increases, the
correlation approaches 1 (Supplemental Text S3, Supplemental
Figures S2 and S3). A more critical metric of accuracy is the
agreement with the training data. The average parameter
strengths inferred from BP and MC are used to calculate the
expected value of the data points. Both MC and BP reproduce the
training data very well as quantified by mean squared error per
data point (Figure 3C). For reference, both BP and MC errors are
at least two orders of magnitude lower than what was expected at
random.
While other parameter search methods such as genetic
algorithms [67], simulated annealing [68], regression [54,69],
Lasso-regression [54], Hybrid Monte Carlo [70,71,72] and
Kalman filtering [73] may offer improvements in speed over the
standard MC comparison used here, they also suffer from poor
scaling properties in the absence of prior knowledge. A statistical-
mechanics analysis demonstrates that BP outperforms mutual
information based inference algorithms since BP takes into
account the collective influence from multiple inputs [74]. We
conclude that BP offers a tremendous speed advantage over MC at
no observable loss of accuracy.
BP reproduces true interactions. BP inference is fast and
almost perfect when the system has been sufficiently explored by
perturbations. In the case of toy data, one can perturb any set of
nodes simultaneously with complete control, and generate
information-rich data sets. Use of rich data sets provided a
sufficient training set for BP to nearly perfectly infer the underlying
system (Supplemental Figure S2 and S3). In biological experi-
mental conditions, however, we are limited by the availability,
strength and specificity of the drugs, by the availability of reporters
(such as antibodies), and by the technical accuracy of the
measurements. We are further limited by the financial and
temporal cost of testing all combinations, even for the drugs that
are available.
Here, we evaluate BP performance in biologically realistic
conditions; small number of sparse perturbations applied individ-
ually and in pairs. The inference is repeated with added noise to
evaluate sensitivity to noise. The Gene Network Generator
GeNGe [75] constructed the structure of positive and negative
interactions for the data generator. The data generator network
contains several common regulatory motifs, including feedback
loops, single/multiple input motifs, multi-component loops and
regular chains. For this study, a drug is represented as exhibiting
strong inhibition of a main target and smaller positive or negative
effects on four or fewer other nodes, which are meant to simulate
off-target effects. Complete knowledge of the perturbations and
off-target effects is used for the noise-free results, while only
knowledge of the main targets is used for the noisy data results,
thus mimicking inference on drugs with unknown off-target effects.
We simulate the system to steady state in response to each
condition of 14 in silico drugs applied individually and in pairs. The
steady state profiles are recorded and serve as the training data,
while those conditions that oscillate are excluded.
Ultimately, the predictive power of the inferred models can only
be assessed by explicit simulation of individual models and
comparison with experiment. However, the average value of the
BP inferred probability distributions can be used in a descriptive
sense and either guide human intuitive understanding of biological
pathways or be compared to prior knowledge.
The performance features for evaluating the inferred interac-
tions are recall and precision. Recall is the fraction of interactions
from the data-generating network that are correctly inferred by BP
marginals. False negatives decrease the recall fraction. Precision is
the fraction of interactions inferred from BP marginals that are
also in the data-generator. False positives lower the precision
fraction.
The average interactions from the BP marginals yield a sparse
network with a significant number of true interactions (Figure 4A).
Importantly, some incorrectly inferred interactions are not
mutually exclusive of correctly inferred interactions. That is, since
each row of W is inferred independently (Assumption 2), one
might expect a row to be either all correct or all incorrect, yet
many rows in Figure 3B have both true and false inferences.
Figure 4. Detailed performance on a single synthetic data-
generating network. The average parameters from the BP distribu-
tions are compared with the true interactions in the synthetic data
generator. The color-coded matrix (A) summarizes all inferred and true
interactions. While BP recovers many of the true interactions, some of
the interactions are missing (orange; false negatives) while others are
incorrect (yellow; false positives). We identified three compensatory
motifs (B), which relate false positives to false negatives. Collectively,
these classes of compensatory motifs contribute to most of the false
negatives (C) and false positives (D). In D, we’ve also included a
category for interactions that have a significant probability of being
zero (a non interaction). Even in the presence of considerable noise, (E,
F) a significant number of interactions are correctly captured and most
of the falsely inferred edges participate in compensatory motifs.
doi:10.1371/journal.pcbi.1003290.g004
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Interestingly, false positives and false negatives are somehow
structurally related. In other words, BP tends to miss one or more
true interactions (false negatives) and replace them with one or
more compensatory interactions (false positives) that are structur-
ally adjacent to the missed interactions. We observe three common
structural correlation motifs, which we refer to as (a) upstream, (b)
symmetric, and (c) co-regulation motifs (Figure 4B).
In the upstream motif, nodes A and C are connected through an
intermediate node B, but an edge is inferred from A to C directly.
In the symmetric motif, a false positive connects two directly
connected nodes but in the wrong direction. In the co-regulation
motif, node A directly regulates B and C separately, but a false
positive exists between B and C directly. In addition to being
structurally correlated, the numerical correlation between nodes
involved in false positives are observably high in the training data
(Supplemental Figure S1).
BP misses 17 of the 60 true interactions, giving a recall of 74%.
Only 4 of these 17 false-negatives are not involved in one of the
three structural correlation motifs. Meanwhile, BP predicts 37 false
positive interactions for a precision of 55%. However, 29 of these
are either involved in one of the three motifs or have a significant
probability of being zero (and therefore ceasing to be false-
positives). Consequently, we conclude that while many of the false
positives may seem worrisome, they are supported in the data and
in the underlying data-generating network.
The results on this toy data confirm that this implementation of
BP has trouble disambiguating correlation and causation from
steady-state data, which is a difficulty common in analysis of
steady-state data [76]. BP infers interactions between highly
correlated nodes even if they are not causally connected. BP is
better able to infer causality when there is sufficient perturbation
of the nodes involved in a potential interaction.
It is likely that the assumptions inherent in this BP algorithm
may cause the incorrect edge predictions, in particular assumption
2, which separates the likelihood function from the dynamics of
the system. We expect that combining a tailored likelihood
function to incorporate time-series data may dramatically improve
the ability of a similar BP method to infer causality more
efficiently.
The inference of network parameters is only moderately
sensitive to noise. With toy data, we can accurately analyze
the effect that noisy data has on the accuracy of inferring network
interactions. Noise from measurement technology can have
deleterious effects on network inference and introduce sensitivity
to data outliers. For example, RPPA produces Gaussian distrib-
uted data in the absence of substantial biological variability [77].
We estimate a coefficient of variance (CV) of 15% on the
measurements from RPPA. To examine the effects of Gaussian
noise on BP inference, we apply Gaussian distributed noise (G0,c)
with a mean of zero and a standard deviation of c representing the
CV as in Equation 16.
Equation 16
x
m
i~x
m
i (1zG0,c)
We construct two data sets with added Gaussian noise; one with
a realistic CV of 15% (c~0:15) and one with high CV of 30%
(c~0:3) as a worst-case scenario. Though both recall and
precision decrease with added noise (Figure 4E, 4F), the number
of unexplained interactions stays roughly constant. Importantly,
BP is still able to identify key regulatory influences from the noisy
steady-state data from sparse perturbations without any depen-
dence on prior knowledge.
This analysis of BP inferred interactions is limited to a thorough
examination of a single set of interactions, taken as the average of
each parameter from the BP generated marginal probabilities. We
demonstrate that BP is fast, accurate and minimally sensitive to
realistic amounts of noise. Moreover, BP is sufficiently strong in
distinguishing causal from correlated relationships even though we
are currently limited to steady-state data from a small set of
perturbation conditions. We know how good the inference of
interactions is in a scenario where a perfect model of the data
generator exists. The comparison gives us an idea of the structural
plausibility of the interactions inferred in real biological contexts.
Network models of signaling pathways in melanoma
cells
The probabilistic nature of the BP algorithm is the key feature
that enables de novo inference on large and complex problems in
cell biology, e.g., signaling processes involving more than a
hundred molecular and phenotypic variables, which previous
methods could not reach. Given this opportunity, we apply our
network pharmacology approach to SKMEL-133, a melanoma
cell line resistant to the RAF inhibitor (Vemurafenib, PLX4032),
which inhibits the BRAFV600E mutant protein kinase more
strongly than other RAF proteins.
Experiments: Systematic perturbation of SKMEL-133
cells using drug pairs. We systematically perturb SKMEL-
133 cells with a panel of 8 targeted drugs (Figure 5) used singly and
in pairwise combinations totaling 44 unique experiments. The set
of perturbations includes the 8 drugs applied individually at two
unique doses (low and high) and all pairs of the 8 drugs at the
single low dose. The drugs are selected on the basis of their target
specificity, availability and usability in clinical settings. The
selected drugs predominantly target the PI3K/AKT and MAPK
pathways, which are known to affect the response to RAF and
MEK inhibitors in some melanoma cell lines and clinical samples
[78,79,80,81,82]. Drug doses are chosen based on the measured
effect of each single drug on a presumed downstream effector of its
target. The changes to presumed targets are measured with
Western blot experiments in different drug concentrations, and
protein IC40 values are estimated from the dose-response curve
(Supplemental Figure S4). Protein IC40s are the drug concentra-
tions that reduce the abundances of a presumed downstream
effector by 40%; compared to proliferation IC-values, which relate
drug doses to phenotypes such as cell viability, protein IC-values
tend to be much smaller than the proliferation IC-values.
As an example, the AKT inhibitor (AKTi) concentration is
chosen based on reduction in AKT phosphorylation at S473
(AKTpS473). The drug dose response curve indicates that
,5000 nM of AKTi is required to reduce AKTpS473 levels by
40% compared to untreated controls. Therefore, 5000 nM is the
so-called protein IC40. In this study, we choose to work with
protein IC40 concentrations, which is a compromise between the
competing requirements of gentle perturbations and observable
effects.
The main intent of the systematic perturbations is to explore
diverse aspects of the signaling response and to maximize
information in the response profiles for model inference.
Experiments: Observation of response profiles in
SKMEL-133 cells. We use an array technique (reverse phase
protein arrays, RPPA [83]), in which cell lysates are interrogated
by antibodies against proteins and phospho-proteins of interest.
Compared to Western blot assays, RPPA has the advantage of
higher throughput, higher sensitivity and better dynamic range.
These are crucial advantages for the quantitative inference of
network models. However, unlike Western blots, RPPA cannot
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separate stain based on size, which limits the number of suitable
antibodies and puts high specificity requirements on RPPA
antibodies. Three independent biological replicates are spotted
for each experimental condition. After perturbation, we quantify
the response for each protein as the log2-ratio of the measured
level in the perturbed condition against the measured level in the
untreated control condition. In this work, a response refers to a
log2-ratio value. Viability of the cells after drug perturbation is
measured using a resazurin assay 72 hours after the cells are
perturbed.
Concept of network models of signaling in SKMEL-
133. Collectively, the responses for 16 protein/phospho-proteins
and the cell viability phenotype from the 44 perturbation
conditions constitute the training data for de novo network
inference. We also include 8 activity nodes (see Methods section)
to represent the perturbed but unmeasured activity of the drug
targets. We build network models of signaling pathways in the
melanoma cell line SKMEL-133 to predict the response of
inhibition to single and multiple protein targets. We expect the
network models to generate hypotheses about previously uniden-
tified interactions, some of which may be accessible to biochemical
experimental tests. Further, these models provide a quantitative
and intuitive model of the signaling cascades in SKMEL-133 cells
and predict novel single drug targets that may be effective in
reducing cell proliferation. In future work, we expect similar
models will guide discoveries to overcome or prevent the
emergence of drug resistance.
Leave-k-out tests of predictive power of network
models. In order to test the accuracy and the predictive power
of the models, we use a leave-k-out cross validation test. For each
leave-k-out test, we withhold k experiments from the training data,
infer network models from the corresponding subset of training
data, predict response profiles (via simulation) for the withheld
perturbation conditions, and then compare the predicted profiles
against those from the withheld test data. Specifically, each leave-
k-out test focuses on the removal of a single drug from the training
data; all combinations involving the drug of interest are removed,
leaving only data from the experiment in which the drug of
interest was applied alone (single dose). For each test, we generate
1000 network models with the BP guided decimation algorithm
and keep only the top 100 models (those with lowest error in the
training set). Overall, eight sets of network models are generated;
one for each of the 8 unique drugs.
High correlations between simulated and withheld experimental
profiles indicate substantial agreement for each of the 8
independent tests (Figure 6). The comparison reveals an overall
Figure 5. Systematic perturbation experiments. (A) Perturbation experiments with systematic combinations of eight small molecule inhibitors,
applied in pairs and as single agents in low (light green) and high (dark green) doses. The perturbation agents target specific signaling molecules,
detailed in the table. The listed drug dose is the standard drug dose (light green), and two times the standard dose was used for the high dose
conditions (dark green). The degree of response is the approximate ratio of downstream effector levels in treated condition compared to untreated
condition. (B) The response profile of melanoma cells to perturbations. The response profile includes changes in 16 protein levels (total and phosho-
levels, measured with RPPA technology) and cell viability phenotype relative to those in no-drug applied condition. The slashed-zero superscript
denotes the unperturbed data.
doi:10.1371/journal.pcbi.1003290.g005
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Pearson correlation coefficient of 0.87, with a cross-validation
error CV=0.05 (see Methods) between experimental and
predicted response profiles (Supplementary Figures S7 and S8).
Such high correlation suggests genuine predictive power.
Average network as a guide. 1000 unique models are
drawn via the BP guided decimation algorithm. From those, the
top 100 models are kept for the analysis. The marginal
distributions before decimation (Figure 7A, left) and after
decimation (Figure 7A, right) reveal substantial similarity. Some
notable discrepancies (e.g., interaction from RbpS807 to
4EBP1pS65) may reflect the effects from mutually exclusive
interactions, where two high probability interactions never occur
in the same model configuration. Such phenomena illustrate the
value of recalculating BP to handle conditional dependencies as
interactions are fixed during model construction.
For simplicity of interpretation and visualization, a single
network representing the set of average interactions, called the
‘average network’, is presented (Figure 7B). These are the average
interaction strengths across the top 100 models. Note that the
average network is not suitable for simulation-based predictions.
However, the average network depicts the qualitative features of
the high probability region of solution space by reporting
interactions that are present at high frequency across a set of
good models. Remarkably, the average network captures many of
the signaling interactions within the major pathways important for
melanoma progression, particularly the canonical (accepted as
standard) MAPK or PI3K/AKT pathways. In addition, the
average network is suggestive of a series of additional interactions
(see Supplementary Table S1 for details), some of which may
represent novel biochemical interactions and are good candidates
for follow-up experimental investigation and validation.
The network’s description of pathways is limited to the scope of
observed model variables. The details of our network may deviate
from the intricate details of canonical pathway models due largely
to the existence of unobserved nodes. As a natural consequence,
the predictions we generate from our networks are also limited by
the scope of observed model variables. As the scope expands, the
network models may converge to the detailed pathway descrip-
tions with additional capacity for context-specific quantitative
predictions.
Interpretation: AKT pathway. The canonical PI3K/AKT
pathway is characterized by a series of complex interactions
resulting from the activity of the upstream kinase PI3K and
reaching more downstream regulatory proteins [84]. Although the
detailed spatiotemporal regulation of the PI3K/AKT pathway
and its phenotypic output ranging from proliferation to metabolic
changes are highly complex, our average network captures the
major known interactions in this pathway.
The indirect positive effect of PI3K on AKT phosphorylation,
phosphorylation of TSC2 on T1462 by AKT activity, the
regulation of S6 and 4E-BP1 by the PI3K/AKT pathway are all
represented in the inferred average network. In our network,
amTOR, the activity of mTOR, has no upstream node. This is an
artifact of our modeling approach, which prohibits incoming
interactions to unmeasured activity nodes. However, the interac-
tion connecting TSC2pT1462 to 4E-BP1pS65 links the upstream
components of the pathway to the downstream components. An
inhibitory interaction from amTOR to AKTpS473 in the PI3K/
AKT pathway is reminiscent of the reported feedback loops in this
pathway [85].
Interpretation: MAPK pathway. In the RAF/MEK/ERK
pathway, the average network captures many of the known
interactions that link the MAPK activity to Cyclin D1 levels and
Rb phosphorylation [86]. However, the interactions that link this
pathway to cell viability are indirect through phosphorylated 4E-
BP1 and have a relatively low effect on this phenotype (See below
for a quantitative predictions). The network has a bidirectional
interaction between PLK1 and Cyclin B1 [87]. A strong direct
Figure 6. Predictive power of network models. Eight distinct leave-7-out cross validation calculations indicate a strong fit between the
predicted and experimental response profiles. In each cross-validation experiment, network models are inferred with partial data, which lacks
responses to all combinations of a given drug. Next, network models are executed with in silico perturbations to predict the withheld conditions. The
cumulative correlation coefficient in all conditions between predicted and experimental profiles is 0.87 (CV= 0.05). Few prediction outliers deviate
from experimental values more than 1 s (standard deviation of the experimental values, dashed lines).
doi:10.1371/journal.pcbi.1003290.g006
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interaction between PLK1 and cell viability is also present in the
network, consistent with the known PLK1 and Cyclin B1
regulation of the G2 to M transition in the cell cycle and the
multifaceted role that PLK1 plays in mitosis, including spindle
formation [87].
Prediction: Logical and biochemical interactions in the
melanoma cell line. In addition to the agreement with well-
studied biological interactions, the average network also indicates
a series of potentially novel interactions.
First, a strong bidirectional interaction is inferred between
RbpS807 and MEKpS217. One hypothesis for the MEK to Rb
interaction is that it stands in for the known direct RAF to Rb
interaction in the absence of any measurements of phosphorylated
RAF. Disruption of the RAF to Rb interaction induces apoptosis
in melanoma [88,89]. Conversely, the Rb to MEK interaction has
not been previously reported. Given that RAF, RAS, and MAPK
are all in the same pathway with MEK, the Rb to MEK
interaction is plausibly consistent with the observations that: (i)
RB1 (the gene that encodes the Rb protein) and KRAS double-
knockout mice studies indicate genetic interaction between Rb and
KRAS [90]; and (ii) inactivation of Rb results in elevated RAS and
MAPK activity [91,92]. It is important to note that the
phosphorylation of Rb on S807 is an inhibitory modification, so
a positive interaction from RbpS807 to MEKpS217 is consistent
with Rb inhibition causing an increase in phosphorylated MEK
levels.
An inhibitory interaction from aHDAC (activity of HDAC) to
SRCpY527, a critical phosphorylation site for the auto-inhibition
of SRC [93], is consistent with the direct and indirect interactions
of HDAC isoforms with Src observed in multiple cancer contexts
[94,95]. Finally, positive interactions connecting Cyclin D1 and
TSC2pY1462 to the SRCpY527 node are inferred. To the best of
our knowledge, no such interactions have been reported. The
observed edges may correspond to logical indirect interactions that
Figure 7. The distribution of edges in all network models and average network model. The probability distribution of edge values (wij)
after BP (A, left) are similar to the histograms of the corresponding interactions after decimation (A, right). An interaction strength is nonzero when it
has high amplitude and frequency in solution space. We generate instantiated models with BP guided decimation algorithm followed by gradient
descent optimization. According to the agreement between the distributions in two panels, BP probability distribution and final model histogram are
similar to each other with important exceptions. The BP guided decimation algorithm goes beyond simply sampling from the BP models and may
encounter features such as mutual exclusivity during the creation of the final models. (B) The average network model over the 100 best solutions with
lowest error capture known interactions such as those in the RAF/MEK/MAPK and PI3K/AKT pathways. The opacities of the edges scale with the
absolute probability of the edges. Note that the letter 9a9 is prefixed to so-called activity nodes as explained in Methods section.
doi:10.1371/journal.pcbi.1003290.g007
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coordinate negative feedback loops acting on Src from the MAPK
and PI3K pathways. All of the predicted interactions are
suggestive of follow-up genetic and/or biochemical experiments.
Prediction: drug target identification in SKMEL-133 via
computation of viability changes in response to previously
untested perturbations. Given a set of network models of
SKMEL-133 cells, we predict the effect of arbitrary in silico
perturbations acting on any protein node present in the model.
Such in silico perturbations predict the quantitative effects of
hypothetical drugs (i.e., virtual drugs that target the nodes in a
model) on the cellular phenotypes. Furthermore, one can
quantitatively track signaling processes beyond the qualitative
interpretation of the average network model.
As an example, we predict the cell viability response of
SKMEL-133 cells to various targeted perturbations via explicit
numerical simulations of our network models. The simulations for
each of the network models produce predictions of the temporal
trajectories for all model nodes: proteins, phospho-proteins and
phenotypes, alike. In each simulation, a single perturbation to a
single protein node i is encoded as an external force (ui) that
reduces the relative abundance of that node by 50% (xi= -
log2(0.5) =21), which in turn propagates throughout the network
model. The simulated steady-state responses to four particular,
individually perturbed target nodes predict substantial decrease in
cell viability (Figure 8) and therefore represent potential novel,
efficacious drug targets.
The most significant reduction in cell viability comes from the
predicted response to perturbation of STAT3pS705, whose mean
predicted inhibition of cell viability is roughly 56%, i.e., 44% of
the unperturbed cell viability (xi=21.16). In the average network,
STAT3pS705 is downstream of aPKC, and our perturbation
experiments do show that PKC inhibition leads to low cell counts.
Thus, the response of STAT3pS705 inhibition simply reflects the
effect of known PKC inhibition, which is included in the training
set. Next, perturbation of both PLK1 and Cyclin B1 protein nodes
lead to significant reduction in cell viability at 45% (xi=20.85)
and 38% (xi=2.69) inhibition, respectively. PLK1 and Cyclin B1
are two important cell cycle proteins regulating G2 to M transition
and highly specific PLK1 inhibitors are potential agents in
targeted therapy [96]. Importantly, the network approach predicts
the effect of PLK1 and Cyclin B1 perturbations on cell viability
without any training to responses of perturbations to these nodes.
We subsequently tested one of these predictions in the lab by
treating the SKMEL-133 cells with the PLK1 inhibitor (BI 2536)
and measuring cell viability response with the resazurin assay
(Figure 9). The experimental tests reveal that the cell viability IC50
for the PLK1 inhibitor is 5.5nM in SKMEL-133 cells and that
approximately 99% of the cells are eliminated with a 15nM
concentration.
The fourth perturbation that predicts significant change in cell
viability is TSC2pT1462 inhibition, which has a central role in the
average network model, particularly in PI3K/AKT pathway. It is
regulated by AKTpS473 and also interacts with MAPK14pT180,
which is upstream of PLK1 and Cyclin B1 in the models. Note
that SKMEL-133 cell line is PTEN-null and that a constitutively
active PI3K/AKT pathway may play a role in drug resistance in
this cell line [46]. Thus, it is not surprising to us that deactivation
of a central player in this pathway leads to reduction in cell
viability. The corresponding best drug target is the kinase that
leads to phosphorylation of TSC2 on T1462.
The predicted effect on cell viability for each of these four
computationally perturbed nodes has at least one of the following
explanations: consistent with known perturbation responses of
immediately adjacent nodes, present in model training; consistent
with the known genetic background of the model cell line (e.g.,
SKMEL-133 is PTEN-null); or represents a genuinely novel drug
Figure 8. Novel predictions from in silico perturbations. (A) The histogram of phenotypic response profiles to the four most effective virtual
perturbations from the best 100 network models. The response to STAT3p705 reflects the effect of PKCi on cell viability. Viability changes in response
to perturbations on cell cycle proteins PLK1 and Cyclin B1 are genuine predictions from the network models. Perturbation of TSC2pT1462 (inhibitory
phosphorylation) down regulates the PI3K/AKT pathway and leads to a decrease in cell viability in the PTEN null SKMEL133 cell line. (B) The perturbed
nodes that lead to reduction in cell viability in the context of average network model (Circled in red).
doi:10.1371/journal.pcbi.1003290.g008
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target, predicted to be highly efficacious and subsequently
validated experimentally.
Discussion
Beyond classical molecular biology
We describe a combination of experimental and computational
methods, in the field of network pharmacology, to construct
quantitative and predictive network models of signaling pathways.
The particular contribution is a set of algorithmic advances, which
we adapted from statistical physics to infer network models in sizes
and complexities not reachable by classical gene-by-gene molec-
ular biology. The necessity of inference of complex network
models stems from the fact that classical methods, in which a small
number of perturbation experiments lead to functional description
of carefully selected sets of genes and gene products is reaching
technical limits. High-throughput proteomic and genomic profil-
ing technologies provide much richer and more complex
information about cellular responses than can be analyzed by a
scientist’s thought processes. At these levels of completeness and
detail, predicting changes in physiological attributes from molec-
ular data requires computational modeling and quantitative
analysis. Our quantitative network models not only capture
already known biological interactions but also nominate novel
interactions and may detect complex regulatory mechanisms, such
as feedback loops, in specific biological contexts. The quantitative
analysis of molecular and cellular behavior in these models
provides detailed understanding of the coupling between signaling
processes and global cellular behavior. Such understanding is hard
to achieve by reductionist approaches that focus on the relation
between single or few molecules and cellular processes. Further-
more, we provide a systems biology platform to predict the cellular
(i.e., proteomic and phenotypic) response profiles to multiple
perturbations such as those in combinatorial cancer therapies.
Network pharmacology in the era of personalized
medicine
This investigation constitutes a proof-of-principle of a particular
technology: a combination of a network inference algorithm and a
technology for perturbing cells and measuring their response. The
overall context is network pharmacology, by which we mean the
science of using network models to derive and then test effective
therapeutic targets and combinations. The particular challenge in
cancer biology is the complexity and individual variation of
genetic and epigenetic alterations that are plausibly cancer
causing, and thus modulate the response to therapy; and, the
emergence of resistance to successful targeted therapies, such as
EGFR inhibitors in lung cancer or RAF inhibitors in melanoma.
In our view, the fairly fragmented gene-by-gene classical methods
of molecular biology, while extremely powerful as a reductionist
method, are reaching a clear limit. Those methods struggle with
effects such as ‘cross-pathway coupling’, ‘multigenic diseases’ or
individual variation of response to therapy. More comprehensively
quantitative and computationally predictive methods (‘systems
biology’) are likely not only to increase our predictive abilities but
also save substantial overall effort by computationally testing large
numbers of cellular states on a large variety of genetic backgrounds
and in exhaustively explored perturbation conditions.
Figure 9. Experimental testing of computational predictions. Qualitative analysis of networks from in silico simulations nominates PLK1 and
Cyclin B1 as potential targets to kill RAF inhibitor resistant melanoma cells. A validation experiment with the PLK1 inhibitor BI2536 shows extensive
growth inhibition in SKMEL133 cells (Cell viability IC50 = 5.8 nm). PLK1 inhibitor is a pure prediction of the approach and was not included in the
experimental drug set.
doi:10.1371/journal.pcbi.1003290.g009
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Power and limitations of the belief propagation method
for network modeling of signaling pathways
The implementation of our BP algorithm enables us to infer
much larger network models than are reachable with standard
Monte Carlo search methods. First, we use biologically realistic toy
data to illustrate the dramatic speed improvement of the BP
method over standard MC methods. BP convergence times scale
favorably with the size of the models at no measureable loss of
accuracy. This is a desirable property for constructing large
network models de novo. Even in the biologically realistic conditions
of noisy data from sparse perturbation, BP infers most of the
dominant interactions in the data-generating network. Although a
fraction of the likely BP interactions are false positives, these false
positives are consistent with the data and connect structurally
correlated nodes. The assumptions inherent in this BP implemen-
tation are potential limitations to the overall efficacy and accuracy
of our approach. However, assumption 1, while important, does
not dramatically affect the results beyond a critical level of
discretization. Furthermore, since BP performs as well or better
than MC, which employs neither assumption 3 nor 4, we suspect
by process of elimination that assumption 2 is the largest
contributor to the observed limitations of our current method.
For real biological data, the quality of BP’s performance depends
on the applicability of the model equations and both the richness
and quality of the data used for training.
We previously published an MCF7 breast cancer cell line
dataset, for which network models were derived with a nested MC
search algorithm (CoPIA) [97]. Reassuringly, many of the
strongest interactions from CoPIA are recovered by the BP
method (Supplementary Text-S4, Figure S10). We have also
modeled the same SKMEL-133 dataset with Gaussian Graphical
Models, a popular probabilistic model that goes beyond pairwise
correlations to distinguish between direct and indirect correlations.
A comparison to the BP derived interactions suggests non-trivial
overlap in the strongest couplings. A more detailed analysis is
available in the supplement (Supplementary Text –S5, Figures S11
and S12). Finally, we have also compared BP against both prior
knowledge models and Bayesian network models inferred with
Bayesian inference [98]. That analysis indicates superior perfor-
mance for the BP derived models for at least this kind of data and
this style of model (See Supplemental Text S7 and Figure S17).
Confirmed and predicted interactions in malignant
melanoma cells
We are able to capture the known interactions in MAPK and
AKT/PI3K canonical pathways through de novo network infer-
ence. Moreover, we predict potential interactions, either direct or
indirect, such as a bidirectional interaction between Rb and
MAPK pathways and a potential feedback loop from PI3K and
MAPK pathways acting on SRC activity through inhibitory
phosphorylation at SRCpY527. We also quantitatively predict the
effect on cell viability from inhibition of novel targets via explicit in
silico simulation. The in silico perturbations of Cyclin B1 and PLK1
lead to comparable reduction in cell viability. As neither Cyclin
B1/PLK1 nor their direct regulators are inhibited for the model
training dataset, this result is a genuine and nontrivial prediction.
We test and validate the PLK1 prediction by measuring the cell
viability after treating SKMEL-133 cells with a potent and
selective PLK1 inhibitor. Indeed, the PLK1 inhibitor reduces
cellular growth significantly in SKMEL-133 cells even when
treated with the drug at nanomolar concentrations (Figure 9).
Moreover, none of the in silico perturbations of the MAPK
pathway lead to a significant change in cell viability, which is
consistent with the experimental responses to perturbations acting
on MEK and BRAFV600E and RAF inhibitor resistance of
SKMEL-133 cells.
The problem of drug specificity
We are aware that drugs do not usually have a single specific
target. While this is potentially problematic for modeling and
simulating drug effects, we find that the inference is driven largely
by the correlations in the data arising from the effect of
perturbations on the overall system. We estimate that BP is most
sensitive to strong and untrue assumptions about the direct effects
of a given drug. The use of activity nodes is an indirect way of
dealing with off-target drug effects. These nodes, which are
perturbed but not measured, represent the coupling of a drug to
the rest of the system. Such coupling includes both specific and off-
target effects. BP may infer interactions from these activity nodes
to any number other measured nodes thus simultaneously
inferring targets for the particular drug used. Drug specificity also
affects the predictive power of the resulting models. All effects from
the AKT inhibitor, for example, are assigned to single inhibition of
the aAKT node, even if other targets of the AKT inhibitor are
partially responsible for the measured outcomes. Therefore, any
simulation-based prediction regarding perturbation of the aAKT
node will be tethered to the off-target effects of the AKT inhibitor
used in training. The complete solution of the drug specificity
problem requires a more comprehensive and systematic analysis to
determine the effect of off-target effects on quality and predictive
power of inferred models.
Failed predictions and optimal design of experiment
The leave-k-out analysis reveals few outlier points, where the
predicted response profiles largely disagrees with test data. These
(mis)predictions fall into two major categories. In the first category,
(mis)predictions arise due to measurements with very low signal to
noise ratios and high experimental uncertainties. The (mis)pre-
dicted S6pS240 levels and cell viability phenotypes in some of the
perturbation conditions fall into this category. Note that the
models are trained and simulated after logarithmic conversion (i.e.,
xi= log2-ratios of measured signals), which exaggerates the errors
for low signals. In linear space, no such outliers are observed
suggesting that those outliers can be considered as an artifact of
our analysis in logarithmic space. In the second category,
(mis)predictions arise due to insufficient experimental constraints.
(Mis)prediction of AKTpS473 levels after mTOR inhibition falls
into this category. mTOR inhibition leads to an increase in AKT
phosphorylation possibly due to the disruption of a feedback loop.
In our current analysis, mTOR inhibition and steady state
measurements on AKT phosphorylation are the sole experimental
inputs to detect the changes in this feedback mechanism. When
the mTOR inhibition is withheld in leave-k-out tests, experimental
constraints become insufficient to describe the regulation of AKT
phosphorylation, thus leading to the (mis)predictions. A systematic
experimental design to enrich the perturbations, better character-
ization of the AKT phosphorylation dynamic range and richer
proteomic measurements on this part of signaling pathways are
possible ways to improve the quality of these particular predic-
tions. In general, careful optimization of perturbation conditions
(drugs and combinations) and observations (protein arrays, mass
spectrometry target list), within available resources, would
significantly enhance the predictive power of this approach.
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Predicting effective novel drug combinations with BP
based network modeling
Predicting the effect of drug combinations is highly challenging
and has been the subject of many studies, e.g., [99,100]. When a
large repertoire of targeted drugs are available for screening, the
search space for useful combinations of two or more drugs is
combinatorially complex. Moreover, therapeutically promising
drug combinations are not limited to simultaneously introduced
perturbations. Potentially useful drug combinations may consist of
combinations of relative doses, for two, three and four drugs
applied simultaneously or sequentially after well-defined time
intervals. Identification of such complicated combinations through
experimental screening tests is prohibitively cumbersome. Here,
we provide a potential solution to this problem in that in silico
screens using predictive network models can cover a large space of
possible drug combinations. The predictive power of the models
derived here is apparent from the reasonable accuracy of
predicting the results of withheld experiments using a leave-k-out
cross validation. Network models inferred from perturbation
experiments can thus be used to predict the responses to novel
combinations. One can enlarge the search space for drug
treatments from a few hundred experimentally screened combi-
nations to tens of thousands of computationally tested combina-
tions and guide subsequent, highly efficient experimental screens
of the top predicted candidates.
Beyond the computational power of well-constrained and
robustly derived network models, one may expect to achieve a
conceptual understanding of the principles of epistasis of drug
effects and the mechanisms of resistance to targeted therapeutics.
For example, the initial system response to drug intervention on
the scale of minutes to days may be indicative of subsequent
epigenetic and genetic changes in a population of treated cells that
represent the long-term and hard-to-treat emergence of drug
resistance. In this context, reliable dynamic network modeling may
be an excellent guide to strategies for blocking the emergence of
resistance in the first place. The pre-clinical consequence is the
selection of combinations of therapeutic interventions that not only
are effective in slowing the proliferation or promoting the
elimination of cancer cells, but also counteract resistance to
otherwise effective treatments, such as RAF inhibitors in
melanoma or AR inhibitors in advanced prostate cancer, in
clinical trials.
Method improvement
While the approximate solutions to the problem of network
inference deliver interpretable biological results, there is much
room for improving the power and information value of the
method. For example, when time-dependent response measure-
ments after perturbation are available, one can use analogous,
extended algorithms to infer probability distributions over (time-
independent) interaction parameters W that describe the behavior
of a time-dependent system. Another extension of the formalism is
the use of more complicated forms of the differential equations,
such as those of enzyme kinetics. Also, even in the current
approximation, careful design of experiments selecting a minimal
set of maximally informative perturbation conditions would
increase the efficiency of this experimental-theoretical approach.
A straightforward and powerful extension is the systematic use
of prior information in the form of directed interactions adapted
from the current scientific literature or pathway databases. Such
prior information is easily incorporated as a set of additional
constraints on the probability distributions of W in Equation 3.
This has been utilized in our related work on modeling
dedifferentiated liposarcoma drug combinations [43]. We are also
actively pursuing a method for the systematic inclusion of prior
knowledge interactions from curated databases. On the experi-
mental side, measurement of richer phenotypic attributes of cells,
such as apoptosis or cell cycle arrest, as well as markers of
differentiation states would greatly increase the predictive power
by providing more links between molecular and phenotypic
quantities.
The network pharmacology approach described here provides a
strong tool for a system level description of signaling events in
cancer cells. Moreover, it presents a step forward in quantitative
prediction of responses of cancer cells to drug perturbations.
Beyond cancer biology, there is no reason to believe that the
proposed technology cannot be used to derive accurate quantita-
tive and predictive network models for biological cellular systems
in general, provided sufficiently diverse experimental perturba-
tions and sufficiently rich readouts are accessible. In this way, we
hope to extend the power of classical molecular biology to a broad
spectrum of cellular systems with targeted, and possibly clinical,
applications.
Materials and Methods
Materials
Choice of drugs and drug concentrations. Eight small
molecule drugs targeting mainly the MAPK or AKT/PI3K
pathways were chosen based on the knowledge of target specificity
and relevance for exploring BRAF signaling in SKMEL-133 cells
(Figure 5). In order to select an appropriate drug concentration for
the RPPA assay, Western blots were used to measure the dose-
response effect of each drug on its presumed targets or
downstream effectors (Supplementary Figure S4). We use the so-
called ‘protein IC-values’, which are the concentrations that
inhibit the most immediate downstream protein by a certain
percentage. This is in contrast to the more common proliferation
IC-values, which are the concentrations that reduce the number of
proliferating cells by a certain percentage
RPPA and western blots. For Western blotting and reverse-
phase protein arrays (RPPA) assays, BRAFV600E mutant
SKMEL-133 cells were grown in 6-well plates to around 40%
confluence in RPMI-1640 medium containing 10% fetal bovine
serum (FBS). In a series of perturbation experiments, cells were
perturbed with 8 drugs either singly or in paired combinations,
and harvested after 24 hours by collecting and freezing the cell
pellet. Non-perturbed control cells were treated with drug vehicle
(DMSO) for 24 hours (elsewhere called ‘‘no-drug control’’). Cells
were thawed, lysed and protein concentrations were determined
by the Bradford assay. Protein concentrations were adjusted to 1–
1.5 mg/mL and proteins denatured in 2% SDS for 5 minutes at
95uC. For RPPA, cell lysates were spotted on nitrocellulose-coated
slides in Gordon Mills’ laboratory at MD Anderson Cancer
Center, as described previously [83] and stain with antibodies.
Each sample was represented in triplicates originating from three
different biological samples (wells). The resulting antibody staining
intensities are quantified using the MicroVigene automated RPPA
module (VigeneTech, Inc.) and normalized as describes in [83].
Resazurin cell viability assay. Cells were grown in 6-well
plates and perturbed in the same way as for the RPPA assays.
After 72 hr drug treatment, resazurin (Sigma-Aldrich, Catalog #
R7017) was added at a final concentration of 44 mM to each well
and the fluorescent signals were measured after 1 hr incubation,
using 530 nm excitation wavelength and 590 nm emission
wavelength. For control wells (0 hr drug treatment), the fluores-
cent signals were monitored after 4 hr incubation. Standard curves
of cell numbers were generated as well to back calculate the cell
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numbers in different wells. Cell viability measurements at 72 hours
are used to ensure the phenotypic responses reached to steady
state. Significant phenotypic response is observed as a conse-
quence of changes in relatively early proteomic responses to drug
perturbations. Indeed, analysis of cell viability changes at 0, 24, 72
and 120 hours after drug perturbations revealed no significant
changes in cell viability between 72 and 120 hours. Conversely,
the cell viability response at 24 hours had not reached steady state.
Methods
Setting up belief propagation calculations for network
inference. Network models are constructed using the mea-
sured proteomic and phenotypic response profiles to drug
perturbations as experimental data. The reported network
models contain 25 nodes and are trained to protein plus
phenotype response profiles from 44 experimental observations.
Each measured protein level is log normalized with respect to its
measured level at no-drug control condition. For quantification of
the activity nodes, see below. The probability distribution for
each possible interaction strength in the system is computed using
the belief propagation algorithm. In the current implementation,
the edge strengths can assume values within the interval [21, 1]
with discrete steps of 0.2. The initial messages are sampled
uniformly from a random distribution and the BP algorithm is
run until the difference between marginals in consecutive
iterations is less than 1026.
The inverse-temperature scaling constant b and the complexity
penalty term l are the parameters in the BP algorithm that
influence expected network connectivity. A systematic approach is
taken to ensure the right approximate connectivity in the network
models in order to prevent both non-descriptive, sparse models
and overfit, highly connected models. Very sparsely connected
network models have discontinuities in information flow and low
predictive power. Overfit models lack generalizability of predictive
power. Empirical representations of signaling networks in the
extant literature are fairly sparse, with approximately 1–2
interactions per node. Generally, one has to select b and l from
a set of BP calculations with systematically varied b and l such
that a typical BP derived network has a desired connectivity (edges
per node). In this work, we explored b and l values in the interval
(0,5.0], and selected the b and l which resulted in the lowest
expected error among the representative networks that had a
desired connectivity of ,1.5 edges per node. Representative
networks in this case were based on the most probable parameter
value for all parameters, each from their respective marginals; we
also set a threshold of 0.2 below which parameters were set to
zero. The optimal values (b=2, l=5) are used for the
computation of the instantiated solutions in subsequent decimation
calculations. For each node. ai is taken as 1 and ei is estimated
from the dynamic range of each proteomic measurement sampled
in the biological dataset. The ei and ai parameters are further
optimized with a gradient descent algorithm.
Inferring distinct, executable network models of
signaling. Distinct model solutions are computed with the BP-
guided decimation algorithm. The interaction parameters in each
model are further optimized using the Pineda gradient descent
algorithm [33], relaxing the assumptions of discrete interaction
values and factorized probability distributions (Equation 6d). The
gradient descent algorithm also includes optimization of both ei
and ai parameters. The optimized models are ranked according to
their model errors and the best 100 models are used for
simulations and the average network model (Supplementary
Figure S6). The average network model is for summary and
illustration purposes and is not in itself executable. Instead,
predictions are made by simulation of individual, or sets of,
instantiated network models.
Simulating signaling network models. Each network
solution is simulated individually with specific virtual perturbations
according to the model Equation 1 until the system reaches its
steady state (Supplementary Figure S9) i.e., until no system
variable changes in consecutive steps of simulation within machine
precision. The DLSODE integration method (ODEPACK) [101]
is used in simulations (default settings with, MF=10, ATOL=1e-
10, RTOL=1e-20) is used for simulations. Trajectories for the
best 100 model solutions yield an ensemble of predicted outcomes
in response to in silico perturbations.
Activity nodes. ‘‘Activity node’’ is a technical term defined
within the context of applied perturbations and derived network
models (Figure 7-Right, Supplemental Figure- S15). Each activity
node quantitatively represents a molecular process or reaction,
such as phosphorylation, involving a particular protein (or other
signaling molecule) that is affected by a perturbation agent. Since
we measure protein and phospho-protein levels and do not directly
measure the biochemical activity of any kinase, the activity nodes
stand in for the effect of each drug perturbation on the
biochemical activity of the drug targets. At a basal level (no
perturbation), the quantitative measure of an activity node is equal
to the activity level in no-drug control experiments and is set equal
to 0 as a reference point. In the presence of an inhibitor molecule
affecting a particular activity node, it is calculated based on the
influence of the drug on its presumed immediate or downstream
target validated with Western blot experiments (Supplementary
Figure S4). We demonstrate this with an example quantification of
the MEK activity node (aMEK). We measure the strength of a
MEK inhibitor by measuring the phosphorylation of its down-
stream target MAPK1 at residue T202. If the level of MAPK
phosphorylation inhibition is 55% compared to a no-drug control
experiment, the strength of the inhibition is ui= -
log2(0.55) =20.863. Based on the model equations (Equation 1),
the value for the activity node is xi= (b/a) tanh(ui) =20.697. The
a/b is initially assumed to be 1 and refined by the final gradient
descent optimization step. Activity nodes are not allowed to have
any upstream regulators except the inhibitor since we do not have
any direct measurement of the activity node. All of the activity
nodes are quantified using the above procedure and the responses
from presumed targets.
Mathematical description of perturbations. A constant
perturbation (ui) acting on a particular node i (Equation 1) impacts
both the time derivative and the final steady state value (xi) of the
perturbed node. The set of interactions and their strengths (wij) are
independent of the perturbation. As modeled by Equation 1, the
dynamic properties and steady state value of node xi are a
functions of the combination of influence from all upstream nodes
(xj) with nonzero interaction strengths wij and the strength of the
perturbation. The perturbation term in Equation 1 models the
effect of targeted interventions such as targeted small molecules.
The model equation can also incorporate other perturbation forms
such as genetic alterations or RNA interference (RNAi). In case of
genetic alterations, the impact can be modeled by fixing xi to a
desired value. For example, fixing a particular xi value to a large
negative value (large relative to a given dataset) represents genetic
knockdown of the corresponding gene, such as perturbations with
RNAi. One may also fix the value of xi to a positive value to model
the impact of amplification of a gene product (e.g., DNA copy
number change).
Toy data. We generated toy data based on toy network
models in order to test the performance of BP against a known set
of true interactions. The toy models are generated by first fixing a
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topology of positive and negative values, which are then assigned a
set of real values by drawing from an even distribution between 0
and a maximum strength of 2. The topologies are designed to
represent cascade-like hierarchical networks to include parallel
chains, feed-forward and feedback motifs. For the analysis focusing
on true interactions, the topology is generated with the web-service
Gene Network Generator (GeNGe). At the time of this analysis,
popular toy data generators such as GeneNetWeaver focus on
scale-free like network topologies that are common in gene
regulatory networks, but not typical for signal transduction
pathways. Given the network model, the data is generated by
simulating the model according to Equation 1 in response to
external perturbation, until the system reaches a stable steady
state. The steady state values for all nodes are recorded in each
perturbation condition. In rare cases, the simulations encountered
perpetual oscillations and these results are excluded from the final
toy data set. These simulations are purely deterministic as no
stochasticity is incorporated into the simulations. Noise is added to
the data post-simulation. We chose to simulate the dynamics of the
toy networks with Equation 1 so as to remove the choice of model
equation as a source of error.
Supporting Information
Code S1 This directory contains all of the fotran90
source code for performing all of the Belief Propagation,
gradient descent and simulation analysis described in
this paper.
(ZIP)
Data Set S1 This directory contains all of the
SKMEL133 perturbation and protein data analyzed in
this paper and is properly formatted to work with the
provided version of the BP code.
(ZIP)
Data Set S2 This directory contains all of the models
and data analyzed in Supplemental Figure S17. The data
in this directory is from a separate study of dedifferentiated
liposarcoma from the DDLS8817 cell line.
(ZIP)
Figure S1 Comparison of the correlations between
false-positives and true-positives. The nodes connected by
false positive edges inferred by BP tend to be highly correlated
(blue dots in Figures S1A and S1B), as analyzed here for two
example false positives, each from different false positive motifs.
Indeed the falsely connected nodes seem to have stronger
correlation than the nodes connected by real edges (red and
green dots). This analysis indicates that BP is indeed capturing
significant correlations in the data although through false
interactions. It also indicates that the edge parameters that BP
misses (red and green edges) are somehow compensated by the
false positive parameter (blue edges). In the absence of temporal
data or more perturbations of the nodes in this sub-network, there
may not be sufficient evidence to correctly infer the causal
relationship between these connected nodes.
(TIF)
Figure S2 Alternative higher-order perturbations pro-
duce better data for inference with BP than the
systematic pair perturbation strategy. Performance for
both datasets is analyzed with mean squared errors (A), recall (B),
precision (C), and the total number of BP-inferred interactions (D).
The correlations between the training patterns are shown in
analyzed in (E) for both perturbation strategies.
(TIF)
Figure S3 Perfect BP inference with ideal data. Totally
randomized data (A) produces low correlations between training
patterns (B). With this maximally informative, BP reproduces all of
the true interactions (D), except 2 with zero false positives when
compared against the underlying data generating network (C).
(TIF)
Figure S4 Dose response curve of singe agent drug
perturbations. Dose response curves determined based on
Western Blot experiments, shown on top. See table S1 for protein
IC40 values, which are calculated with these curves and used in all
paired perturbation experiments. Cell viability curve (not shown)
was used to estimate PKC inhibitor (Ro-31-7549) IC40.
(TIF)
Figure S5 Model abstraction in network models of
signaling. A relatively detailed model of biochemical events in
PI3K/AKT pathway (i.e. consecutive phosphorylation of AKT at
T308 and S473) (reactome.org) and the coarse-grained network
model abstraction used in this paper (Red arrows and rectangles).
In the model abstraction, PI3K and AKT activity nodes influence
the final output of the activation mechanism (i.e. AKTpS473). In
princible, we can improve and extend the model with additional
measurements such as measurements on PDK1, AKTp308
(circled in gray) etc without altering the model abstraction. Such
model improvement requires richer measurements and will lead to
a shift from logical to potential physical interactions. Lower left.
The PI3K/AKT interactions in the average network model
computed with BP-guided decimation.
(TIF)
Figure S6 6 of the 10 best network models. Better models
have lower cost. Two nodes (horizontal and vertical list) can be
connected by a positive (red) or negative (blue) interaction Wij.
Although each model is different in detail, each model represents
the data well in the predictive sense. The differences reflect
genuine uncertainties of model inference, normally not represent-
ed in molecular biology cartoon models. Substantial similarity
exists between the top 6 models shown in Figure S6 A–F.
(TIF)
Figure S7 Predictive power tested by prediction of
withheld data. The 8 distinct heatmaps of withheld (upper
right) and predicted (lower right) respone profiles to withheld
perturbations (upper left). For quantitative analysis of predictive
power, please see Figure 7 in the main manuscript.
(TIF)
Figure S8 Cumulative predictive power. The cumulative
scatter plot that combines the information in Figure S7 (C= 0.87).
(TIF)
Figure S9 Sample simulated trajectory. Pseudo-time
trajectory of a single network model when perturbed with an in
silico perturbation on AKTpS473 at virtual IC50 (i.e. log2
([AKTpS47]final/([AKTpS47]initial) =21).
(TIF)
Figure S10 BP comparison with CoPIA results on mcf7
perturbation data. The CoPIA network inference method is an
older method based on a nested Monte Carlo search, and was
previously applied to infer network models of mcf7 breast cancer
data. The CoPIA network edges are color-coded based on the
existence of those edges in BP inference (A) has many agreeing
edges (green). Furthermore, most of the significant BP edges (B)
are also significant in the CoPIA models (green). Further analysis is
available in Supplementary Text – S4.
(TIF)
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Figure S11 Gaussian model couplings for the most
likely cutoff. The inference with no reweighting produces the
highest likelihood estimate (A). The distribution of J and H
couplings (B and C, respectively) are strongly centered at zero,
demonstrating some discerning power between all possible
couplings. Further analysis is available in Supplementary Text –
S5.
(TIF)
Figure S12 Comparison of the most likely Gaussian
model couplings and those from BP. The ROC curve (A)
lies firmly above the diagonal line. The set of GGM edges taken
from the F1-max cutoff (B) has many agreeing edges with those
returned from BP (C). Further analysis is available in Supplemen-
tary Text – S5.
(TIF)
Figure S13 Entropy as a function of the number of bins.
Entropy is normalized by the ratio of total entropy to maximum
possible entropy. This analysis is focused on exploring the effects of
different discretization strategies (Assumption 1) on the BP
inference. Further analysis is available in Supplementary Text –
S1.
(TIF)
Figure S14 Entropy as a function of the number of bins.
This time, entropy is calculated on a collapsed distribution over
three regions; aggregate probability mass for negative values, zero
values and positive values. Further analysis is available in
Supplementary Text-S1.
(TIF)
Figure S15 Schematic illustration of interpreting model
edges and activity nodes. Direct interactions in our models do
not necessarily imply direct biological interactions (A). Rather the
separation between any two connected nodes is dependent on
those nodes that are included in the model, which is in turn a
function of the availability and specificity of assays for various
proteins and phospho-proteins. Consider the linear cascade of 5
nodes (A). When intermediate nodes are excluded from the model,
for whatever reason, the true direct interactions are also excluded.
In their stead, the model will have interactions between the
neighboring nodes. In that case, the direct model interactions do
no correspond to direct biological interactions. The use of activity
nodes may also confuse the interpretation of our model
interactions. Activity nodes stand in for the activity of a protein
(or phosphorylated protein) that is not directly measureable, as
explained in the Materials and Methods section of the main
manuscript. It is this activity that is being targeted by a given drug.
We can assume that the activity is below basal (x is negative) when
the drug is applied. However, in those conditions in which the
drug is not applied we have no data or reasonable assumption with
which to approximate the activity nodes. Consequently we do not
have enough data with which to infer interactions into activity
nodes. Activity nodes are therefore restricted to exist as ‘root
nodes’ such that they have only outgoing edges (B). We consider
the activity nodes to represent the effect of ad rug on the rest of the
model nodes.
(TIF)
Figure S16 Algorithm flow chart.
(TIF)
Figure S17 BP comparison against Bayesian Inference
of Bayesian network models. We compare models created
from both BP and Bayesian inference (BI) against random and
prior knowledge network models. For each class of model, we
compare only the top 100 models based on mean squared error
after simulation. Both BP and BI (purple and yellow, respectively)
outperform both random and prior knowledge models (red and
green, respectively). The analysis shows clear separation between
all four classes of models, confirming that both BI and BP models
are demonstrably informed by the data. Although BP models
outperform BI models in this study, it is unclear whether this is
generally true, which method predicts biological interactions more
accurately, or how low the MSE should be for genuine predictive
power to novel perturbations. See Supplementary Text S7 for
more information.
(PDF)
Table S1 This table provides notes curated from the
literature for each of the most probable interactions
inferred by BP for the melanoma data described in this
paper.
(DOCX)
Text S1 Discretization of parameter space. This section
focuses on the consequences of different strategies for discretizing
the network parameter space.
(DOCX)
Text S2 Monte Carlo inference. This section described in
detail the Monte Carlo inference method used in the comparison
studies in this manuscript.
(DOCX)
Text S3 Training patterns. This section contains results from
an in silico experiment comparing the informative value of data
from systematic low order perturbations (drug pairs) against
random higher order perturbations (more than two drugs) with
respect to BP inference.
(DOCX)
Text S4 MCF7. This section examines BP performance on a
previously published dataset of perturbation responses in breast
cancer from the MCF7 cell line. This section also compares BP to
our previously published method for inferring models based on a
greedy Monte Carlo search.
(DOCX)
Text S5 Gaussian graphical models. This section reports
the results of modeling the melanoma data described in this
manuscript with Gaussian Graphical Models; a popular and
statistically rigorous method for discriminating between direct and
indirect correlations between system variables.
(DOCX)
Text S6 Implementation details. This section briefly
explains some of the more tedious details regarding implementa-
tion of the BP algorithm described in this paper.
(DOCX)
Text S7 Comparison with Bayesian Inference. This
section reports the results of a preliminary comparison of BP
models against those inferred from Bayesian Inference. It also
compares both class of models to random models and prior
knowledge models. The data used in this preliminary study is from
similar perturbation experiments on the dedifferentiated liposar-
coma cell line DDLS8817.
(DOCX)
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